European Academic Research ISSN 2286-4822
ISSN-L 2286-4822
Impact Factor: 3.4546 (UIF)
DRJI Value : 5.9 (B+)
Article Details :
Article Name :
The fate of ovarian cancer in an era of immunotherapy
Author Name :
Doomah Yussriya Hanaa, Ying Xiao Yan
Publisher :
Bridge Center
Article URL :
Abstract :
Ovarian cancer is the leading cause of death from gynecologic malignancies with an overall 5-year survival rate of <45%. Most patients are diagnosed at stage III/IV due to the lack of adequate screening biomarkers and the paucity of early symptoms. The gold standard of treatment is aggressive debulking surgery, followed by platinum-based chemotherapy. However, ovarian cancer has a high recurrence rate. Recently, the emergence of immunotherapy has shown promising results in the treatment of various cancers. This has led to the exploration of possible immunotherapeutic options as a second-line treatment for recurrent ovarian cancer. This review focuses on the mechanisms of tumor evasion and the emerging immunotherapeutic options that can improve clinical outcomes.
Keywords :
ovarian neoplasms, immunotherapy, tumor escape, chemotherapy

New Launched Project
Recommend & Share